Publications by authors named "M Livhits"
Article Synopsis
- The study examines thyroid tumors with isolated RAS mutations, comparing their oncologic outcomes to tumors with isolated BRAF mutations using comprehensive molecular testing.
- A total of 368 patients with Bethesda III-VI thyroid nodules were reviewed, revealing that 14% had isolated RAS mutations, with a 46% malignancy rate but no instances of structural recurrence after 5 years.
- The findings suggest that isolated RAS-mutated tumors have lower aggressive characteristics, indicating that thyroid lobectomy may be an adequate treatment option for these patients.
Context: BRAF V600E mutation is the most common genetic driver of papillary thyroid cancer (PTC), where it is found with various allele frequency (AF), reflecting the proportion of cells carrying the mutant and wild-type gene alleles.
Objective: To determine whether BRAF V600E AF can improve prognostication and inform initial surgical management of PTC.
Design: Retrospective cohort study (2016-2019).
Context: Little is known about how patients' emotions impact the choice between hemi- and total thyroidectomy (TT) for low-risk thyroid cancer (LR-TC) and how these emotions change after treatment.
Objective: To investigate thyroid cancer-specific fear and worry both before and after treatment of LR-TC with hemi- or TT.
Methods: This prospective cohort study enrolled adults with confirmed or likely LR-TC at 15 institutions.
Selpercatinib prior to radioactive iodine for pediatric papillary thyroid carcinoma.
J Pediatr Endocrinol Metab
November 2024
Objectives: We introduced selpercatinib prior to radioactive iodine therapy prior to radioactive iodine therapy (RAI) for pediatric papillary thyroid cancer (PTC) to enhance the tumorical effects of RAI.
Case Presentation: PTC has an excellent prognosis but is commonly associated with local and distant metastases. Successful complete response to the current standard of care, thyroidectomy with lymph node resection and RAI, is achieved in only a small minority of cases with metastases.
Article Synopsis
- The study evaluates how patients with low-risk thyroid cancer prioritize treatment outcomes after their surgical choices, emphasizing the emotional impact of their diagnosis on decision-making.
- Participants rated outcomes at the time of surgery decision and again after 9 months, revealing that patients' valuations changed significantly over time.
- Results indicate that after experiencing treatment, patients shifted focus from concerns about cancer recurrence to valuing quality of life aspects like energy levels, suggesting surgeons need to consider these changing priorities in discussions about treatment options.